<DOC>
	<DOCNO>NCT01673295</DOCNO>
	<brief_summary>OBJECTIVE To test whether Rituximab ( RTX ) efficacious achieve complete renal response ( CR ) Lupus Nephritis ( LN ) patient persistent proteinuria ( ≥1g/d ) despite least 6 month standard care ( SOC ) . STUDY DESIGN Investigator-initiated randomize international open multicentric 104-week study .</brief_summary>
	<brief_title>RING - Rituximab Lupus Nephritis With Remission Goal</brief_title>
	<detailed_description>After screen ( week -8 ) , patient enter run-in period 6 week treatment unchanged . At week -2 , persistent proteinuria confirm ( uP/C ratio ≥1 express mg/mg ) , patient randomize 1/1 ratio 1 2 treatment group follow : RTX group Subjects receive RTX infusion ( 1g ) w0 , w2 , w24 , w48 w72.Control group Subjects receive RTX infusion . In arm , azathioprine ( AZA ) mycophenolate mofetil ( MMF ) continue . If prescribe , prednisolone dose &gt; 10 mg/day .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>All following inclusion criterion meet : 1 . SLE , accord ACR and/or SLICC ( Arthritis Rheum 2012 ; May 2 ; doi : 10.1002/art.34473 ) criterion ; 2 . Age ≥15y ( except local ethic committee imposes ≥18y ) ; 3 . ISN/RPS 2003 Class III ( A A/C ) , IV ( A A/C ; S G ) V lupus GN confirm renal biopsy perform within 24 month screen ; 4 . Having receive one four follow immunosuppressive regimen : ) : EuroLupus ( EL ) intravenous ( IV ) cyclophosphamide ( CY ) ( 6x 500 mg q2w ) follow AZA/MMF 3 month ; ii ) : NIH IVCY 6M ( 6 monthly pulse ) follow AZA/MMF 3 month ; iii ) : MMF least 6 month dose 2g/day ( maximal tolerate dose ; iv ) : AZA least 6 month dose 2 mg/kg/day ( maximal toerated dose ) . All patient AZA MMF screen . In regimen , MMF replace entericcoated mycophenolic acid ( eMPA ) ; 5 . If GC , maximum 10 mg equivalent prednisolone/d screening ( least 2 week ) ; 6. uP/C ratio ≥1 ( express mg/mg ) measure 24h urine collection , confirm randomization ( w2 ) ; 7 . Contraception ( type ; sexual abstinence alternative contraception paediatric patient ) ; 8 . Signed informed consent ( draft accord local practice approve local ethic committee ) . Any follow : 1 . Recent ongoing renal flare define either ) : fall estimate glomerular filtration rate ( eGFR ; MDRD ) ≥25 % within 3 month prior screen screen randomization ; ii ) : increase urine protein ≥100 % &gt; 3.5g/d compare previous assessment ; 2 . 24h proteinuria decline &gt; 50 % previous 6 month ; 3 . Treatment ≥10 mg equivalent prednisolone/d last 2 week screen ; 4 . Pregnancy breastfeeding ; 5 . Anticipated noncompliance protocol ; 6 . History malignancy ( except nonmelanoma skin cervical intraepithelial cancer ) ; 7 . Previous treatment RTX ( whenever ) previous treatment another biologic agent within last 6 month ; 8 . HIV infection ; 9 . Active HBV/HCV/TB infection ; 10 . Severe liver , cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , haematologic psychiatric disturbance , would contraindicate inclusion protocol , judge clinician .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Lupus Nephritis</keyword>
	<keyword>Rituximab</keyword>
</DOC>